Showing 1191-1200 of 20397 results for "".
Current & Emerging Therapies: Treating & Preventing Hereditary Angioedema Attacks in Children & Adults
https://reachmd.com/programs/cme/current-emerging-therapies-treating-preventing-hereditary-angioedema-attacks-in-children-adults/37604/Provided by RMEI Medical Education, LLC. Supported by independent educational grants from Intellia Therapeutics, Pharming Healthcare, Inc., and Pharvaris.GA Case Compendium: Identification of Geographic Atrophy on Color Fundus Photography
https://reachmd.com/resources/geographic-atrophy-case-compendium/ga-case-compendium-identification-of-geographic-atrophy-on-color-fundus-photography/56702/MS Minute: Disparities in Multiple Sclerosis: Incorporating Equity Into Clinical Care and Research
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/ms-minute-disparities-in-multiple-sclerosis-incorporating-equity-into-clinical-care-and-research/32018/Assessing biologic, genetic, and social factors of patients with MS to shrink the gap in care for underrepresented populations.Oral Contraceptives and Endometrial Cancer: Examining a Potential Dose-Response Protective Effect
https://reachmd.com/programs/project-oncology/oral-contraceptives-and-endometrial-cancer-examining-a-potential-dose-response-protective-effect/35506/As rates of endometrial cancer rise globally, a 2025 meta-analysis offers compelling evidence that oral contraceptives (OCs) could significantly reduce EMC risk. Explore the findings from this new review and its potential implications for the future of patient care.Measuring IgAN Risk: Genetic, Environmental, and Systemic Factors
https://reachmd.com/programs/clinicians-roundtable/measuring-igan-risk-genetic-environmental-and-systemic-factors/29742/Learn about common risk factors for IgA nephropathy.Deciphering IgA Nephropathy: Insights into the Diagnostic Process
https://reachmd.com/programs/frontlines-iga-nephropathy/deciphering-iga-nephropathy-insights-into-the-diagnostic-process/26946/When IgA nephropathy is suspected, it’s important to follow a stepwise pattern to confirm those suspicions. Here’s what the diagnostic process looks like.Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
https://reachmd.com/programs/neurofrontiers/mcdonald-criteria-impacts-ms-diagnosis/56634/Early real-world experience with the 2024 McDonald criteria suggests a meaningful increase in multiple sclerosis (MS) diagnoses, driven largely by recognition of optic nerve involvement and reclassification of radiologically isolated syndrome. Hear from Dr. Aaron Miller as he reviews emergingAI and Hair Loss: Measuring Progress with Data-Driven Insights
https://reachmd.com/programs/clinicians-roundtable/ai-and-hair-loss-measuring-progress-with-data-driven-insights/32933/Explore how devices powered by artificial intelligence can impact the way dermatologists track hair loss through precise data.Next-Gen Clinical Monitoring: Predicting Inpatient Decline with AI-Driven Alerts
https://reachmd.com/programs/the-convergence/clinical-monitoring-inpatient-decline-ai-alerts/39924/An artificial intelligence (AI)-driven clinical alert model has the potential to reshape inpatient care by detecting early signs of deterioration an average of 17 hours before adverse events occur. Dr. Brian McDonough sits down with Dr. Theodoros Zanos, to learn more about how his team combined contManaging AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
https://reachmd.com/programs/project-oncology/akt-inhibitor-ae-hr-positive-her2-negative-advanced-bc/54763/In HR+/HER2- advanced breast cancer, effective management of AKT inhibitor-associated adverse events (AEs) begins well before treatment initiation. To learn more about how proactive planning and patient-centered strategies can help reduce the risks of hyperglycemia, rash, and diarrhea, Dr. Charles T